Analysts See $-0.14 EPS for Stellar Biotechnologies, Inc. (SBOT)

January 12, 2018 - By Nellie Frank

 Analysts See $ 0.14 EPS for Stellar Biotechnologies, Inc. (SBOT)

Analysts expect Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to report $-0.14 EPS on February, 5.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.12 EPS previously, Stellar Biotechnologies, Inc.’s analysts see 16.67 % EPS growth. The stock increased 7.61% or $0.07 during the last trading session, reaching $0.99. About 215,798 shares traded or 135.10% up from the average. Stellar Biotechnologies, Inc. (NASDAQ:SBOT) has declined 60.19% since January 13, 2017 and is downtrending. It has underperformed by 76.89% the S&P500.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein primarily in Europe, the United States, and Asia. The company has market cap of $10.42 million. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. It currently has negative earnings. The firm offers its KLH protein under the Stellar KLH brand.

More important recent Stellar Biotechnologies, Inc. (NASDAQ:SBOT) news were published by: Seekingalpha.com which released: “Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships” on June 23, 2016, also Streetinsider.com published article titled: “Stellar Biotechnologies (SBOT) to Sell ‘Immunogen & Vaccine Technology’ to …”, Prnewswire.com published: “Stellar Biotechnologies Expands Operations Team” on June 07, 2017. More interesting news about Stellar Biotechnologies, Inc. (NASDAQ:SBOT) was released by: Prnewswire.com and their article: “Biotech and Pain Management Therapeutics Segments Projected to Grow” with publication date: January 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: